Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Comment by zwerp2000on Feb 21, 2024 9:40am
135 Views
Post# 35890624

RE:I think people r over reacting ...

RE:I think people r over reacting ...You're missing the big picture. Their big revenue driver, IXINITY, is getting slashed big time. So much so they are materially cutting salesforce and efforts to sell it. That is not good at all. This means that revenues will continue to decline as will losses. The other drugs in their portfolio are nothing great so don't expect those to help. Management is a bunch of clowns clearly clueless on how to run a business. The only hope you have is approval of Treo but who knows if/when that will come and even if it;s approved, it will take some time for revenues to build. You can be talking 1-2 years from now if at all. No reason to own this stock when you know revenues will continue to decline, losses will pile up and there is no real catalyst coming near term.
<< Previous
Bullboard Posts
Next >>